Found: 21
Select item for more details and to access through your institution.
Antipsychotic-induced hyponatraemia: a systematic review of the published evidence.
- Published in:
- 2010
- By:
- Publication type:
- journal article
Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 1, p. 119, doi. 10.1007/s10637-015-0309-4
- By:
- Publication type:
- Article
Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5‐fluorouracil toxicity.
- Published in:
- British Journal of Clinical Pharmacology, 2021, v. 87, n. 8, p. 3234, doi. 10.1111/bcp.14742
- By:
- Publication type:
- Article
Food‐effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers.
- Published in:
- British Journal of Clinical Pharmacology, 2018, v. 84, n. 12, p. 2761, doi. 10.1111/bcp.13719
- By:
- Publication type:
- Article
Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers.
- Published in:
- British Journal of Clinical Pharmacology, 2016, v. 82, n. 3, p. 706, doi. 10.1111/bcp.13007
- By:
- Publication type:
- Article
Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine.
- Published in:
- Therapeutic Advances in Medical Oncology, 2019, v. 11, p. 1, doi. 10.1177/1758835919838964
- By:
- Publication type:
- Article
Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine.
- Published in:
- Therapeutic Advances in Medical Oncology, 2019, v. 11, p. N.PAG, doi. 10.1177/1758835919838964
- By:
- Publication type:
- Article
Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.
- Published in:
- 2017
- By:
- Publication type:
- journal article
A Nomogram to Predict Severe Toxicity in DPYD Wild‐Type Patients Treated With Capecitabine‐Based Anticancer Regimens.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 2, p. 269, doi. 10.1002/cpt.3100
- By:
- Publication type:
- Article
Response to "Plasma Uracil as a DPD Phenotyping Test: Pre‐analytical Handling Matters".
- Published in:
- Clinical Pharmacology & Therapeutics, 2023, v. 113, n. 3, p. 473, doi. 10.1002/cpt.2775
- By:
- Publication type:
- Article
Pharmacogenetic‐Pharmacokinetic Interactions in Drug Marketing Authorization Applications via the European Medicines Agency Between 2014 and 2017.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 2, p. 338, doi. 10.1002/cpt.1834
- By:
- Publication type:
- Article
Baclofen overdose treated with continuous venovenous hemofiltration.
- Published in:
- European Journal of Clinical Pharmacology, 2015, v. 71, n. 3, p. 357, doi. 10.1007/s00228-014-1802-y
- By:
- Publication type:
- Article
Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2019, v. 8, n. 12, p. 940, doi. 10.1002/psp4.12474
- By:
- Publication type:
- Article
Effectiveness and safety of reduced‐dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.
- Published in:
- International Journal of Cancer, 2019, v. 144, n. 9, p. 2347, doi. 10.1002/ijc.32022
- By:
- Publication type:
- Article
Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity.
- Published in:
- International Journal of Cancer, 2016, v. 138, n. 11, p. 2752, doi. 10.1002/ijc.30014
- By:
- Publication type:
- Article
Increased risk of severe fluoropyrimidine-associated toxicity in patients carrying a G to C substitution in the first 28-bp tandem repeat of the thymidylate synthase 2 R allele.
- Published in:
- International Journal of Cancer, 2016, v. 138, n. 1, p. 245, doi. 10.1002/ijc.29694
- By:
- Publication type:
- Article
Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis.
- Published in:
- British Journal of Cancer, 2024, v. 130, n. 5, p. 808, doi. 10.1038/s41416-023-02517-2
- By:
- Publication type:
- Article
Clinical outcome in patients treated with simultaneous integrated boost – intensity modulated radiation therapy (SIB-IMRT) with and without concurrent chemotherapy for squamous cell carcinoma of the anal canal.
- Published in:
- Acta Oncologica, 2016, v. 55, n. 6, p. 760, doi. 10.3109/0284186X.2015.1124141
- By:
- Publication type:
- Article
Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study.
- Published in:
- 2016
- By:
- Publication type:
- journal article